Blog
    Peptide SpotlightFor PatientsApril 10, 2026

    Do all peptides work? Evidence and FDA status

    Learn how peptides like Semaglutide and Retatrutide are graded based on clinical evidence, FDA approval status, and reported side effects like weight regain.

    This content is sourced exclusively from TruthTides clinical reference data and does not constitute medical advice.

    Is every peptide a sure thing?

    If you spend five minutes on the internet, you might think peptides are magic dust that solves every human problem. Look, I know it sounds great to believe there is a perfect fix for everything, but the reality is a bit more complicated. Not every peptide is created equal, and some have way more homework done than others.

    Scientists use a grading system to show how much evidence they have. Some get an A+ because they have gone through massive trials, while others are essentially still in the "we hope this works" phase. Understanding the difference can save you a lot of frustration and money.

    The straight-A students

    There are a few peptides that have the gold standard of proof: FDA approval. These have been tested in thousands of people to see what they actually do.

    • Semaglutide [Grade: A+]: This one mimics a natural hormone to reduce your appetite and slow down how fast your stomach empties. In a study called STEP 1, people saw 14.9% weight loss. It is FDA-approved under names like Wegovy and Ozempic.
    • Tirzepatide [Grade: A+]: This is a dual agonist, meaning it hits two different receptors at once for a bigger effect on insulin and appetite. In the SURMOUNT-1 study, it hit 22.5% weight loss. You know this one as Mounjaro or Zepbound.
    • Tesamorelin [Grade: A]: This targets visceral adipose tissue (the deep belly fat). It is FDA-approved specifically for people with HIV-associated lipodystrophy, where it showed an 18% reduction in that specific type of fat.

    The 'Wait and See' group

    Just because a peptide sounds cool doesn't mean the science is finished. Some are promising but still haven't crossed the finish line.

    • Retatrutide [Grade: B+]: This one is a "triple agonist." While it showed 24.2% weight loss in Phase II trials (the highest seen yet), it is still investigational. We are still waiting on Phase III results to see if those early wins hold up.
    • Thymosin Alpha-1 [Grade: A-]: This is an interesting case. It is approved in over 35 countries, but it is not FDA-approved in the US. While it helps with T-cell maturation, its use for things like anti-aging hasn't had the right dosing established yet.
    • MK-677 [Grade: B]: Here is a plot twist: this technically isn't even a peptide; it is a "small-molecule." While it can raise growth hormone levels, it failed in Alzheimer's trials and can actually worsen insulin sensitivity.

    The catch nobody likes to mention

    Even the best peptides have trade-offs. Scientists are still working on the "after" part of the story. For example, with Semaglutide, weight regain after you stop the medication is substantial. There are also concerns about losing muscle mass instead of just fat.

    Then there are the side effects. Semaglutide has over 187,000 reports in safety databases, mostly for gastrointestinal issues. Nausea is common, affecting about 44% of people. More serious stuff, like pancreatitis or intestinal obstruction, has also been flagged as a concern.

    Basically, the human body is complicated. Who knew?

    This is a great one to bring up with your doctor. You can find peptide-experienced physicians in our Find a Doctor directory.

    Referenced Peptides

    semaglutidetirzepatidetesamorelinretatrutidethymosin alpha 1

    This content was generated from TruthTides clinical reference data. It does not constitute medical advice. Always consult a qualified healthcare provider.